186 related articles for article (PubMed ID: 36575558)
1. KW-2449 and VPA exert therapeutic effects on human neurons and cerebral organoids derived from MECP2-null hESCs.
Xu YJ; Liu PP; Yan ZZ; Mi TW; Wang YY; Li Q; Teng ZQ; Liu CM
Stem Cell Res Ther; 2022 Dec; 13(1):534. PubMed ID: 36575558
[TBL] [Abstract][Full Text] [Related]
2. Graded and pan-neural disease phenotypes of Rett Syndrome linked with dosage of functional MeCP2.
Chen X; Han X; Blanchi B; Guan W; Ge W; Yu YC; Sun YE
Protein Cell; 2021 Aug; 12(8):639-652. PubMed ID: 32851591
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D modulates cortical transcriptome and behavioral phenotypes in an Mecp2 heterozygous Rett syndrome mouse model.
Ribeiro MC; MacDonald JL
Neurobiol Dis; 2022 Apr; 165():105636. PubMed ID: 35091041
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological reactivation of inactive X-linked
Przanowski P; Wasko U; Zheng Z; Yu J; Sherman R; Zhu LJ; McConnell MJ; Tushir-Singh J; Green MR; Bhatnagar S
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):7991-7996. PubMed ID: 30012595
[TBL] [Abstract][Full Text] [Related]
5. Multiplex epigenome editing of
Qian J; Guan X; Xie B; Xu C; Niu J; Tang X; Li CH; Colecraft HM; Jaenisch R; Liu XS
Sci Transl Med; 2023 Jan; 15(679):eadd4666. PubMed ID: 36652535
[TBL] [Abstract][Full Text] [Related]
6. MeCP2-regulated miRNAs control early human neurogenesis through differential effects on ERK and AKT signaling.
Mellios N; Feldman DA; Sheridan SD; Ip JPK; Kwok S; Amoah SK; Rosen B; Rodriguez BA; Crawford B; Swaminathan R; Chou S; Li Y; Ziats M; Ernst C; Jaenisch R; Haggarty SJ; Sur M
Mol Psychiatry; 2018 Apr; 23(4):1051-1065. PubMed ID: 28439102
[TBL] [Abstract][Full Text] [Related]
7. 5-HT
Dai H; Kitami Y; Goto YI; Itoh M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430502
[TBL] [Abstract][Full Text] [Related]
8. MeCP2 dysfunction prevents proper BMP signaling and neural progenitor expansion in brain organoid.
Hong H; Yoon SB; Park JE; Lee JI; Kim HY; Nam HJ; Cho H
Ann Clin Transl Neurol; 2023 Jul; 10(7):1170-1185. PubMed ID: 37302988
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological reversal of synaptic and network pathology in human MECP2-KO neurons and cortical organoids.
Trujillo CA; Adams JW; Negraes PD; Carromeu C; Tejwani L; Acab A; Tsuda B; Thomas CA; Sodhi N; Fichter KM; Romero S; Zanella F; Sejnowski TJ; Ulrich H; Muotri AR
EMBO Mol Med; 2021 Jan; 13(1):e12523. PubMed ID: 33501759
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of BRD4 Function Underlies the Functional Abnormalities of MeCP2 Mutant Neurons.
Xiang Y; Tanaka Y; Patterson B; Hwang SM; Hysolli E; Cakir B; Kim KY; Wang W; Kang YJ; Clement EM; Zhong M; Lee SH; Cho YS; Patra P; Sullivan GJ; Weissman SM; Park IH
Mol Cell; 2020 Jul; 79(1):84-98.e9. PubMed ID: 32526163
[TBL] [Abstract][Full Text] [Related]
11. Neural development of methyl-CpG-binding protein 2 null embryonic stem cells: a system for studying Rett syndrome.
Okabe Y; Kusaga A; Takahashi T; Mitsumasu C; Murai Y; Tanaka E; Higashi H; Matsuishi T; Kosai K
Brain Res; 2010 Nov; 1360():17-27. PubMed ID: 20816763
[TBL] [Abstract][Full Text] [Related]
12. Modeling Rett Syndrome Using Human Induced Pluripotent Stem Cells.
Andoh-Noda T; Inouye MO; Miyake K; Kubota T; Okano H; Akamatsu W
CNS Neurol Disord Drug Targets; 2016; 15(5):544-50. PubMed ID: 27071793
[TBL] [Abstract][Full Text] [Related]
13. FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice.
Deng V; Matagne V; Banine F; Frerking M; Ohliger P; Budden S; Pevsner J; Dissen GA; Sherman LS; Ojeda SR
Hum Mol Genet; 2007 Mar; 16(6):640-50. PubMed ID: 17309881
[TBL] [Abstract][Full Text] [Related]
14. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation.
Cheung AY; Horvath LM; Grafodatskaya D; Pasceri P; Weksberg R; Hotta A; Carrel L; Ellis J
Hum Mol Genet; 2011 Jun; 20(11):2103-15. PubMed ID: 21372149
[TBL] [Abstract][Full Text] [Related]
15. Modeling Rett Syndrome with Human Pluripotent Stem Cells: Mechanistic Outcomes and Future Clinical Perspectives.
Gomes AR; Fernandes TG; Cabral JMS; Diogo MM
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916879
[TBL] [Abstract][Full Text] [Related]
16. Wide spectrum of neuronal and network phenotypes in human stem cell-derived excitatory neurons with Rett syndrome-associated MECP2 mutations.
Mok RSF; Zhang W; Sheikh TI; Pradeepan K; Fernandes IR; DeJong LC; Benigno G; Hildebrandt MR; Mufteev M; Rodrigues DC; Wei W; Piekna A; Liu J; Muotri AR; Vincent JB; Muller L; Martinez-Trujillo J; Salter MW; Ellis J
Transl Psychiatry; 2022 Oct; 12(1):450. PubMed ID: 36253345
[TBL] [Abstract][Full Text] [Related]
17. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model.
Ricciardi S; Boggio EM; Grosso S; Lonetti G; Forlani G; Stefanelli G; Calcagno E; Morello N; Landsberger N; Biffo S; Pizzorusso T; Giustetto M; Broccoli V
Hum Mol Genet; 2011 Mar; 20(6):1182-96. PubMed ID: 21212100
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D Supplementation Rescues Aberrant NF-κB Pathway Activation and Partially Ameliorates Rett Syndrome Phenotypes in
Ribeiro MC; Moore SM; Kishi N; Macklis JD; MacDonald JL
eNeuro; 2020; 7(3):. PubMed ID: 32393583
[TBL] [Abstract][Full Text] [Related]
19. Differential brain region-specific expression of MeCP2 and BDNF in Rett Syndrome patients: a distinct grey-white matter variation.
Pejhan S; Siu VM; Ang LC; Del Bigio MR; Rastegar M
Neuropathol Appl Neurobiol; 2020 Dec; 46(7):735-750. PubMed ID: 32246495
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological enhancement of
Tang X; Drotar J; Li K; Clairmont CD; Brumm AS; Sullins AJ; Wu H; Liu XS; Wang J; Gray NS; Sur M; Jaenisch R
Sci Transl Med; 2019 Jul; 11(503):. PubMed ID: 31366578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
